Literature DB >> 29061853

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Carina Mihai1,2, Milos Antic2, Rucsandra Dobrota1,2, Diana Bonderman3, Harbajan Chadha-Boreham4, John Gerry Coghlan5, Christopher P Denton6, Martin Doelberg4, Ekkehard Grünig7, Dinesh Khanna8, Vallerie V McLaughlin9, Ulf Müller-Ladner10, Janet E Pope11, Daniel M Rosenberg4, James R Seibold12,13, Madelon C Vonk14, Oliver Distler2.   

Abstract

OBJECTIVE: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc). In this longitudinal study, we aimed to identify factors associated with an unfavourable outcome in patients with SSc with early PAH (SSc-PAH) from the DETECT cohort.
METHODS: Patients with SSc-PAH enrolled in DETECT were observed for up to 3 years. Associations between cross-sectional variables and disease progression (defined as the occurrence of any of the following events: WHO Functional Class worsening, combination therapy for PAH, hospitalisation or death) were analysed by univariable logistic regression.
RESULTS: Of 57 patients with PAH (median observation time 12.6 months), 25 (43.9%) had disease progression. The following factors (OR (95% CI)) were associated with disease progression: male gender (4.1 (1.2 to 14.1)), high forced vital capacity % predicted/carbon monoxide lung diffusion capacity (DLCO)% predicted ratio (3.6 (1.2 to 10.7)), high Borg Dyspnoea Index (1.7 (1.1 to 2.6)) and low DLCO% predicted (non-linear relationship).
CONCLUSION: More than 40% of early-diagnosed patients with SSc-PAH had disease progression during a short follow-up time, with male gender, functional capacity and pulmonary function tests at PAH diagnosis being associated with progression. This suggests that even mild PAH should be considered a high-risk complication of SSc. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cardiovascular disease; epidemiology; systemic sclerosis

Mesh:

Year:  2017        PMID: 29061853     DOI: 10.1136/annrheumdis-2017-211480

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.

Authors:  Vivek Nagaraja; Marco Matucci-Cerinic; Daniel E Furst; Masataka Kuwana; Yannick Allanore; Christopher P Denton; Ganesh Raghu; Vallerie Mclaughlin; Panduranga S Rao; James R Seibold; John D Pauling; Michael L Whitfield; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2020-05-18       Impact factor: 10.995

2.  Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature.

Authors:  Hiroki Wakabayashi; Hitoshi Kino; Makoto Kondo; Keiichi Yamanaka; Masahiro Hasegawa; Akihiro Sudo
Journal:  BMC Rheumatol       Date:  2019-04-24

3.  Progression of gastrointestinal symptoms over time in patients with systemic sclerosis.

Authors:  Jamie Bering; W Leroy Griffing; Michael Crowell; Sarah B Umar
Journal:  Rheumatol Int       Date:  2021-02-25       Impact factor: 2.631

Review 4.  Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment.

Authors:  You-Jung Ha; Yun Jong Lee; Eun Ha Kang
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

Review 5.  Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases.

Authors:  Eun Ha Kang; Yeong Wook Song
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-10

Review 6.  An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Francesco Salton; Elisa Baratella; Paola Confalonieri; Pietro Geri; Riccardo Pozzan; Chiara Torregiani; Roberta Bulla; Marco Confalonieri; Marco Matucci-Cerinic; Michael Hughes
Journal:  Diagnostics (Basel)       Date:  2022-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.